CATX Stock Overview
Develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Perspective Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.17 |
| 52 Week High | US$19.05 |
| 52 Week Low | US$2.28 |
| Beta | 1.47 |
| 11 Month Change | -51.42% |
| 3 Month Change | -58.92% |
| 1 Year Change | 141.96% |
| 33 Year Change | 21.46% |
| 5 Year Change | 17.39% |
| Change since IPO | -38.30% |
Recent News & Updates
Recent updates
Shareholder Returns
| CATX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -37.9% | -6.5% | -1.0% |
| 1Y | 142.0% | 14.6% | 30.3% |
Return vs Industry: CATX exceeded the US Biotechs industry which returned 14.1% over the past year.
Return vs Market: CATX exceeded the US Market which returned 30.4% over the past year.
Price Volatility
| CATX volatility | |
|---|---|
| CATX Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CATX has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CATX's weekly volatility has decreased from 15% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 118 | Thijs Spoor | www.perspectivetherapeutics.com |
Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans.
Perspective Therapeutics, Inc. Fundamentals Summary
| CATX fundamental statistics | |
|---|---|
| Market cap | US$458.24m |
| Earnings (TTM) | -US$57.71m |
| Revenue (TTM) | US$1.56m |
267.8x
P/S Ratio-7.2x
P/E RatioIs CATX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CATX income statement (TTM) | |
|---|---|
| Revenue | US$1.56m |
| Cost of Revenue | US$0 |
| Gross Profit | US$1.56m |
| Other Expenses | US$59.27m |
| Earnings | -US$57.71m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,706.62% |
| Debt/Equity Ratio | 0.5% |
How did CATX perform over the long term?
See historical performance and comparison